Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Total Liabilities (2024 - 2025)

Xilio Therapeutics' Total Liabilities history spans 2 years, with the latest figure at $141.8 million for Q3 2025.

  • For Q3 2025, Total Liabilities rose 164.12% year-over-year to $141.8 million; the TTM value through Sep 2025 reached $141.8 million, up 164.12%, while the annual FY2024 figure was $53.5 million, N/A changed from the prior year.
  • Total Liabilities for Q3 2025 was $141.8 million at Xilio Therapeutics, up from $126.7 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $141.8 million in Q3 2025 and bottomed at $53.5 million in Q4 2024.